Patents by Inventor Elizabeth B. Norton

Elizabeth B. Norton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADJUVANTED CONJUGATE OPIOID VACCINE
    Publication number: 20230181728
    Abstract: The adjuvanted conjugate opioid vaccine described herein is a conjugate of a protein carrier and at least one opioid backbone component or hapten conjugated thereto, admixed with at least one adjuvant. Anti-opioid effects are demonstrated after administration of a vaccine made up of the CRM197 protein carrier linked to a FEN backbone, combined with adjuvants such as dmLT or LTA1.
    Type: Application
    Filed: May 25, 2021
    Publication date: June 15, 2023
    Applicants: University of Houston System, Tulane University
    Inventors: Colin N. Haile, Gregory Cuny, Elizabeth B. Norton, Therese Kosten
  • Primary mesenchymal stem cells as a vaccine platform
    Patent number: 10472647
    Abstract: Episomally transfected primary mesenchymal stem cells (MSC) express a polypeptide consisting of an antigenic polypeptide (e.g., one or more polypeptides) relating to a pathogen (e.g., one or more virus, bacterium, or parasite). The antigenic polypeptide can have the amino acid sequence of a natural polypeptide from the pathogen or an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions. Uses and method for treating or preventing infections with episomally transfected primary MSC also are described.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: November 12, 2019
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Suzanne L. Tomchuck, Elizabeth B. Norton, Robert F. Garry, Bruce Bunnell, John D. Clements
  • PRIMARY MESENCHYMAL STEM CELLS AS A VACCINE PLATFORM
    Publication number: 20140178422
    Abstract: Episomally transfected primary mesenchymal stem cells (MSC) express a polypeptide consisting of an antigenic polypeptide (e.g., one or more polypeptides) relating to a pathogen (e.g., one or more virus, bacterium, or parasite). The antigenic polypeptide can have the amino acid sequence of a natural polypeptide from the pathogen or an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions. Uses and method for treating or preventing infections with episomally transfected primary MSC also are described.
    Type: Application
    Filed: November 15, 2013
    Publication date: June 26, 2014
    Applicant: The Administrators of the Tulane Educational Fund
    Inventors: Suzanne L. Tomchuck, Elizabeth B. Norton, Robert F. Garry, Bruce Bunnell, John D. Clements